Data from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH demonstrated clinically meaningful ...

Mammalian target of rapamycin (mTOR) inhibitors could be associated with acute nephrotoxicity, according to French researchers. The team describes 4 cancer patients who developed severe acute kidney ...

First-in-human study evaluates weekly IV Sapu003 in advanced mTOR-sensitive solid tumors, including HR+/HER2- breast cancer, RCC, NETs, TSC-associated tumors, and HCCSAN DIEGO, Calif., May 13, 2026 ...

Acquisition includes LAM-001, an inhaled formulation of rapamycin for multiple pulmonary diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis ...

Managing the side effects in patients being treated for metastatic breast cancer can be challenging. Recently, Marla D. Lipsyc-Sharf, MD, a breast medical oncologist and health sciences clinical ...

Significant protocol amendments have been made to the ongoing phase 3 VIKTORIA-2 clinical trial (NCT06757634).The study, ...

University of Oxford-led research finds low-dose rapamycin functions as a genomic protector in aging human immune cells, lowering DNA damage. Subscribe to our newsletter for the latest sci-tech news ...

Researchers at Zhejiang University and Zhongshan Institute for Drug Discovery have discovered phosphatidylinositol 3-kinase δ (PI3Kδ) and mammalian target of rapamycin (mTOR; FRAP1) dual inhibitors ...

Kazia Therapeutics Ltd. raised AU$50 million (US$33.15 million) in a private placement of equity securities to advance lead candidate paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor in clinical ...

As people age, their immune systems deteriorate. This makes them more susceptible to infections and can mean that vaccines are less effective. New research carried out by Dr. Loren Kell at NDORMS ...